6,6-二甲基-3-氮杂双环[3.1.0]己烷 | 943516-54-9

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 6,6-二甲基-3-氮杂双环[3.1.0]己烷
• 中文别名: 6,6-二甲基-3-氮杂双环[3.1.]己烷；6,6-二甲基-3-氮杂双环己烷；6-二甲基-3-氮杂双环[3.1.0]己烷
• 英文名称: 6,6-dimethyl-3-azabicyclo[3.1.0]hexane
• CAS: 943516-54-9
• 化学式: C₇H₁₃N
• mdl: MFCD13176114
• 分子量: 111.187
• InChiKey: BGOMFPZIMJCRDV-UHFFFAOYSA-N

物化性质

• 沸点：
  135℃
• 密度：
  0.911
• 闪点：
  24℃

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  3
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

制备方法与用途

6,6-二甲基-3-氮杂双环[3.1.0]己烷是一种杂环有机化合物，可作为医药中间体使用。

反应信息

• 作为反应物：
  描述：

  6,6-二甲基-3-氮杂双环[3.1.0]己烷 在 盐酸 、 MAON₄₀₁ 、 氧气 、 sodium hydrogensulfite 、 sodium hydroxide 、 catalase 作用下， 以 CPME 、 水 为溶剂， 5.0~50.0 ℃ 、128.91 kPa 条件下， 反应 24.5h， 生成 (1R,2S,5S)-6,6-二甲基-3-氮杂双环[3.1.0]己烷-2-羧酸甲酯
  参考文献：
  名称：

  Efficient, Chemoenzymatic Process for Manufacture of the Boceprevir Bicyclic [3.1.0]Proline Intermediate Based on Amine Oxidase-Catalyzed Desymmetrization

  摘要：

  The key structural feature in Boceprevir, Merck's new drug treatment for hepatitis C, is the bicyclic [3.1.0]profine moiety "P2". During the discovery and development stages, the P2 fragment was produced by a classical resolution approach. As the drug candidate advanced through clinical trials and approached regulatory approval and commercialization, Codexis and Schering-Plough (now Merck) jointly developed a chemoenzymatic asymmetric synthesis of P2 where the net reaction was an oxidative Strecker reaction. The key part of this reaction sequence is an enzymatic oxidative desymmetrization of the prochiral amine substrate.

  DOI：

  10.1021/ja3010495
• 作为产物：
  描述：

  卡龙酸酐 在 氨 、 氢气 、 Ni-Cu/SiO₂ 作用下， 以 1,4-二氧六环 为溶剂， 240.0~300.0 ℃ 、4.0 MPa 条件下， 生成 6,6-二甲基-3-氮杂双环[3.1.0]己烷
  参考文献：
  名称：

  一种6,6-二甲基-3-氮杂双环[3.1.0]己烷的合成方法

  摘要：

  本申请公开了一种6,6‑二甲基‑3‑氮杂双环[3.1.0]己烷的合成方法，包括如下步骤：(1)将卡龙酸酐与第一溶剂混合均匀，在第一催化剂的存在下，在氢气气氛中加热反应，得到6,6‑二甲基‑3‑氧杂双环[3.1.0]己烷；以及(2)将6,6‑二甲基‑3‑氧杂双环[3.1.0]己烷与第二溶剂混合均匀，在第二催化剂的存在下，在氨气气氛中加热反应，得到6,6‑二甲基‑3‑氮杂双环[3.1.0]己烷。所述合成方法步骤少、工艺简单、易分离、可连续操作、收率高、减少了三废排放、有利于工业化生产。

  公开号：

  CN115232059A

文献信息

• [EN] MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS MACROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASE TRK ET LEURS UTILISATIONS
  申请人：ANGEX PHARMACEUTICAL INC

  公开号：WO2019094143A1

  公开（公告）日：2019-05-16

  The present disclosure describes novel TRK kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such TRK kinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described.

  本公开描述了新颖的TRK激酶抑制剂及其制备方法。还描述了包含这种TRK激酶抑制剂的药物组合物以及使用它们治疗癌症、感染性疾病和其他疾病的方法。
• [EN] HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLCARBOXAMIDES UTILISÉS EN TANT QU'INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018192866A1

  公开（公告）日：2018-10-25

  Heteroarylcarboxamides of formula (I), wherein A, T, R1, R2 and R3 are as defined in the specification and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.

  式(I)中的杂环羧酰胺，其中A、T、R1、R2和R3如规范和索赔中所定义，并且其药学上可接受的盐可以用于治疗受血浆激肽酶抑制影响的疾病的方法。
• Nickel‐Catalyzed Amination of (Hetero)aryl Halides Facilitated by a Catalytic Pyridinium Additive
  作者：Dongyang Han、Sasa Li、Siqi Xia、Mincong Su、Jian Jin

  DOI：10.1002/chem.202002800

  日期：2020.9.25

  An efficient and operationally simple Ni‐catalyzed amination protocol has been developed. This methodology features a simple NiII salt, an organic base and catalytic amounts of both a pyridinium additive and Zn metal. A diverse number of (hetero)aryl halides were coupled successfully with primary and secondary alkyl amines, and anilines in good to excellent yields. Similarly, benzophenone imine gave

  已经开发了有效且操作简单的镍催化胺化方案。该方法具有简单的Ni II盐，有机碱以及催化量的吡啶鎓添加剂和Zn金属的特征。多种（杂）芳基卤化物与伯，仲烷基胺和苯胺成功偶联，收率良好。同样，二苯甲酮亚胺以优异的收率得到了相应的N芳基化产物。
• [EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS D'ACIDE PYRIDIN-3-YL ACÉTIQUE COMME INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK (NO 5) LTD

  公开号：WO2017025864A1

  公开（公告）日：2017-02-16

  Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. In the compounds of formula (I), R1 is selected from H, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (alkoxy)alkoxyalkyl, or (R6)alkyl; R2 is phenyl substituted with 1 R7 substituent and with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; or R2 is selected from tetrahydroisoquinolinyl, ((Ar1)alkyl)tetrahydroisoquinolinyl, or ((N-alkoxycarbonyl)tetrahydroisoquinolinyl; R3 is is selected from tetrahydroisoquinolinyl or decahydroisoquinolinyl and is substituted with 0-3 substituents selected from halo, alkyl, and haloalkyl; or R3 is a [5-7.3-7.0-2] fused or bridged bicyclic amine and is substituted with 0-3 alkyl substituents; or R3 is selected from azetidinyl, pyrrolidinyl, piperidinyl, or homopiperidinyl and contains a spirocyclic moiety wherein the spirocyclic moiety, including the carbon atom to which it is attached, forms C3-7 cycloalkane, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, N-alkylpyrrolidinyl, piperidinyl, N-alkylpiperidinyl, homopiperidinyl, or N-alkylpiperidinyl, and wherein the spirocyclic moiety is substituted with 0-3 halo or alkyl substituents; R4 is selected from alkyl or haloalkyl; R5 is selected from H, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (alkoxy)alkoxyalkyl, or (R6)alkyl; R6is selected from (oxetanyl)oxy, ((oxetanyl)alkoxy)alkyl, (tetrahydropyranyloxy)alkyl, (tetrahydropyranyl)alkoxy)alkyl, or (Rg)(R9)N; R7 is selected from (Ar1)alkoxy or ((Ar1)alkyl)HNCO; R8 is selected from hydrogen, alkyl, (cycloalkyl)alkyl, alkoxyalkyl, (tetrahydropyanyl)alkyl, tetrahydropyanyl, or alkoxyphenyl; R9 is selected from hydrogen or alkyl; or (R8)(R9)N taken together is selected from azetidinyl, pyrrolidinyl, piperidinyl, (spirocyclobutyl)piperidinyl, piperazinyl, or morpholinyl; and Ar1 is phenyl substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.

  化合物的结构式（I）包括药学上可接受的盐，包含这些化合物的药物组合物，制备这些化合物的方法以及它们在抑制HIV整合酶和治疗HIV或艾滋病感染者中的用途。在结构式（I）的化合物中，R1从H，烷基，卤代烷基，羟基烷基，烷氧基烷基，（烷氧基）烷氧基烷基或（R6）烷基中选择；R2是苯基，其上取代有1个R7取代基，以及从卤素，烷基，卤代烷基，烷氧基和卤代烷氧基中选择0-3个取代基；或者R2从四氢异喹啉基，（（Ar1）烷基）四氢异喹啉基，或（（N-烷氧羰基）四氢异喹啉基中选择；R3从四氢异喹啉基或十氢异喹啉基中选择，并取代有从卤素，烷基和卤代烷基中选择的0-3个取代基；或者R3是[5-7.3-7.0-2]融合或桥接的双环胺基，并取代有0-3个烷基取代基；或者R3从氮杂环丙烷基，吡咯啉基，哌啶基，或异哌啶基中选择，并含有一个螺环结构基团，其中螺环结构基团，包括与其相连的碳原子，形成C3-7环烷烃，四氢呋喃基，四氢吡喃基，吡咯啉基，N-烷基吡咯啉基，哌啶基，N-烷基哌啶基，异哌啶基，或N-烷基哌啶基，并且螺环结构基团取代有0-3个卤素或烷基取代基；R4从烷基或卤代烷基中选择；R5从H，烷基，卤代烷基，羟基烷基，烷氧基烷基，（烷氧基）烷氧基烷基或（R6）烷基中选择；R6从（氧杂环丙烷基）氧，（（氧杂环丙烷基）烷氧基）烷基，（四氢吡喃氧基）烷基，（四氢吡喃基）烷氧基）烷基，或（Rg）（R9）N中选择；R7从（Ar1）烷氧基或（（Ar1）烷基）HNCO中选择；R8从氢，烷基，（环烷基）烷基，烷氧基烷基，（四氢吡啶基）烷基，四氢吡啶基，或烷氧基苯基中选择；R9从氢或烷基中选择；或者（R8）（R9）N共同选择自氮杂环丙烷基，吡咯啉基，哌啶基，（螺环丁基）哌啶基，哌嗪基，或吗啉基；Ar1是苯基，其上取代有从卤素，烷基，卤代烷基，烷氧基和卤代烷氧基中选择的0-3个取代基。
• The Use of Potassium/Sodium Nitrite as a Nitrosating Agent in the Electrooxidative <i>N</i> ‐Nitrosation of Secondary Amines
  作者：Ying Wang、Shiqi You、Mengyao Ruan、Feiyi Wang、Chao Ma、Cuifen Lu、Guichun Yang、Zuxing Chen、Meng Gao

  DOI：10.1002/ejoc.202100363

  日期：2021.6.14

  An efficient and environmentally electrooxidative N-nitrosation of secondary amines using potassium/sodium nitrite as nitrosating agents has been developed. This strategy break through the innate combination of sodium nitrite and a strong acid. The reaction is compatible with the late-stage modification of pharmaceutical compounds and could be conducted in gram scale with high reaction efficiency.

  已经开发了一种使用亚硝酸钾/亚硝酸钠作为亚硝化剂的仲胺的有效和环境电氧化N-亚硝化。这种策略突破了亚硝酸钠和强酸的先天组合。该反应与药物化合物的后期修饰相容，可以以克级规模进行，反应效率高。